Takis srl Listed by Deadlock Ransomware Group: What Was Exposed & What To Do

On 28 July 2026, the Italian biotechnology firm Takis srl appeared on a leak site operated by the ransomware group known as Deadlock. Public reporting states that internal files were exfiltrated in a ransomware attack; the number of people affected remains unknown, and fuller technical detail has not been released. For anyone whose personal or professional information may sit inside those files—employees, research partners, contractors, or others who have dealt with the company—the practical question is straightforward: what was taken, who might see it, and what can be done now.

Because the listing itself is a claim by the threat actor and independent confirmation of the full scope is limited, the picture is incomplete. What follows sets out only what has been reported, places the incident in context, and outlines concrete steps for people who may be affected.

Breaking down the breach

According to the available record, Takis srl was listed by the Deadlock ransomware group on 28 July 2026. The reported summary describes internal files as having been exfiltrated in a ransomware attack. No public figure has been given for the volume of data, the number of individuals involved, or the precise date the intrusion began. The method of initial access, the duration of the attackers’ presence, and whether encryption was also deployed on internal systems have not been disclosed in the material provided.

Ransomware incidents of this type commonly involve both theft of data and a threat to publish it if a ransom is not paid. In this case the public evidence consists of the group’s listing and the statement that internal files were taken. Beyond that, operational specifics remain undisclosed. Readers should treat the leak-site entry as an unverified claim by the actor unless and until the company or independent investigators confirm additional facts.

Who is Deadlock?

Deadlock is a ransomware operation that has appeared in public reporting as a group practising double extortion: encrypting systems while also copying data and threatening to release it. Like other actors in this category, Deadlock has used dedicated leak sites to name victims and, in some cases, to stage samples or larger archives of stolen material when negotiations stall. Public tracking of such groups shows they typically target organisations across multiple sectors rather than a single industry, favouring whatever access yields leverage.

No statement from Deadlock beyond the listing of Takis srl is included in the facts at hand. Therefore any assertion that the group made specific demands, published particular files, or set a deadline in this incident would be unsupported. The listing is recorded here solely as the group’s claim that it holds data belonging to the company.

About Takis srl

Takis srl, also referred to in reporting as Takis Biotech, is an Italian biotechnology company founded in 2009 and headquartered in Rome. It specialises in contract research and development services, preclinical immunology, and the development of genetic vaccines and therapeutic antibodies. Organisations of this kind routinely handle scientific data, partner and client information, employee records, and proprietary research materials under confidentiality and regulatory obligations.

A breach affecting such a firm is consequential because the data it holds can include both commercially sensitive intellectual property and personal information belonging to staff, collaborators, and study-related contacts. Even when the exact contents of an exfiltration remain unconfirmed, the sector’s normal data holdings make the incident relevant to a wider circle than the company alone.

The information in question

The facts name the exposed material only as “internal files exfiltrated in a ransomware attack.” No inventory of file types, no count of records, and no confirmation of whether personal data, health-related research data, or credentials were included has been supplied. Exact contents are therefore unconfirmed.

Biotechnology and contract-research organisations typically maintain personnel files, email and messaging archives, research protocols, partner contracts, and laboratory or clinical-support data. Any of those categories could in principle be present among internal files; none should be assumed present until verified. Public detail on what Deadlock actually copied from Takis srl is limited to the general description already stated.

Why it matters

For individuals, the core risks are misuse of personal or professional information that may have been stored in the company’s systems—identity fraud, targeted phishing that references real projects or colleagues, or exposure of contact details. For the organisation, the stakes include potential disruption of research partnerships, regulatory notification duties, and loss of confidence among clients who entrust it with confidential work. Because the scale and precise data types remain unknown, the severity for any single person cannot yet be measured; the prudent stance is to assume that material linked to one’s dealings with Takis srl could be in the hands of the attackers until clearer information emerges.

If your data was in this breach

If you have worked with, been employed by, or otherwise shared information with Takis srl, treat the possibility of exposure seriously while recognising that confirmation is still incomplete. Practical first steps include:

• Change passwords for any accounts that used the same or similar credentials as those associated with the company, and enable multi-factor authentication where it is available.
• Watch for unexpected emails, calls, or messages that reference internal projects, colleagues, or personal details; verify such contacts through known channels before responding.
• Review financial and identity-monitoring tools you already use for unusual activity, and consider placing fraud alerts if you believe sensitive identifiers may have been involved.
• Retain any official notices the company may issue; they remain the primary source for confirmed scope and recommended actions.
• Run a free exposure scan of your email address to check whether it has already appeared in known breach datasets elsewhere, which can help you prioritise further hardening of accounts.

Further public detail may clarify what was taken and who is affected. Until then, measured caution—stronger authentication, scepticism toward unsolicited contact, and attention to official updates—is the most useful response.

AICompiled with AI assistance from public sources and published under our editorial standards.